Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? by van der Veek, Patrick P. J. et al.
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2011, Article ID 123743, 4 pages
doi:10.1155/2011/123743
Case Report
TwoPatients withExtremelyElevated TumorMarkers: WhereIs
theMalignancy?
Patrick P. J. van der Veek,1 Wouter H. de Vos tot Nederveen Cappel,2
Alexandra M. J. Langers,3 andBartvanHoek3
1Departments of Internal Medicine, Gastroenterology, and Hepatology, Medisch Centrum Haaglanden, P.O. Box 432,
2501 CK The Hague, The Netherlands
2Department of Gastroenterology and Hepatology, Isala Clinics, P.O. Box 10500, 8000 GM Zwolle, The Netherlands
3Department of Gastroenterology and Hepatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
Correspondence should be addressed to Patrick P. J. van der Veek, p.vanderveek@mchaaglanden.nl
Received 3 March 2011; Accepted 26 April 2011
Academic Editor: Stuart Sherman
Copyright © 2011 Patrick P. J. van der Veek et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Serum tumor markers are useful to evaluate a cancer’s response to treatment, for early detection of cancer relapse, and, in
some cases, to diagnose malignancy. In this paper, we present two patients with signiﬁcantly elevated serum tumor markers
without evidenceofmalignantdisease.An18-year-oldpatientsuﬀeringfromautoimmunehepatitishadmarkedlyincreasedalpha-
fetoprotein (aFP) levels (2,002µg/L; normal <10ug/L). Extensive imaging showed no signs of hepatocellular carcinoma or other
cancer, and treatment with Prednisoneled to rapid normalization of both liver enzymes and aFP. The second patient, a 60-year-old
female with painless jaundice due to biliary stone disease, had very high serum levels of CA19-9 (18,000kU/L, normal <27kU/L).
Liver biochemistry and serum CA19-9 concentration decreased to almost normal values (45kU/L) after biliary stenting. These
cases demonstrate that serum tumor markers can be elevated in benign disease and are therefore not appropriate to diagnose
cancer.
1.Introduction
Serum tumor markers are useful to evaluate a cancer’s
response to treatment, for early detection of cancer relapse,
and, in some cases, to diagnose malignancy. Here, we present
two patients with signiﬁcantly increased serum tumor mark-
ers without evidence of malignant disease.
2.CaseA
An 18-year-old male patient was admitted for progressive
jaundice, which had started after an episode of binge drink-
ing during a holiday in Italy 5 months before presenta-
tion. Jaundice had been intermittently present since but
had worsened during the last few weeks. He suﬀered
from unusual fatigue and nonspeciﬁc upper abdomi-
nal pain that was not related to meal ingestion. Urine
and stools were normal. On admission, he had stopped
drinking alcohol for several months and denied any drug
abuse. Physical examination showed a mild jaundice but
was otherwise unremarkable. Laboratory tests revealed a
mild macrocytic anemia (hemoglobin 7.3mmol/L (normal
(N) 8.5–11.0mmol/L), MCV 101ﬂ (N 80–100ﬂ), and
marked elevation of liver biochemistry (total biliru-
bin 100µmol/L (N 0–17µmol/L), conjugated bilirubin
64µmol/L (N 0–5µmol/L), alkaline phosphatase (ALP)
155U/L (N 40–120U/L), gamma-GT (gGT) 254U/L (N
5–55U/L), aspartate aminotransferase (AST) 1,025U/L (N
5–35U/L), alanine aminotransferase (ALT) 656U/l (N 5–
45U/L)). Antibodies against smooth muscle (ASMA) and
nuclei (ANA) were positive, and gamma globulin level was
elevated (IgG, 25.1g/L; N 7.0–16.0g/L)), suggesting autoim-
mune hepatitis. Anti-DNA was negative. Remarkably, alpha-
fetoprotein (aFP) concentration, which was routinely mea-
sured in the standard workup for patients with liver enzyme
abnormalities, was also signiﬁcantly increased to 2,002µg/L2 Gastroenterology Research and Practice
(upper limit of normal (ULN) 10µg/L). Test results for hep-
atitis A, B, and C, Epstein-Barr virus, Cytomegalovirus,
and antimitochondrial antibodies were all negative. No ev-
idence was found for Wilson’s disease, hemochromatosis;
alfa-1-antitrypsine genotype was partly deﬁcient (PI-MS)
but quantitative analysis was normal. Urinalysis was also
completely normal. Abdominal ultrasound showed normal
liver parenchyma without focal liver lesions and no signs
of portal hypertension. Because of the extraordinary aFP
increase, an additional abdominal CT scan was performed
to exclude hepatocellular carcinoma (HCC), seminoma, and
nonseminomatousgermcelltumor,allofwhichcouldnotbe
demonstrated. Liver biopsy showed a periportal and lobular
inﬂammatory inﬁltrate, piecemeal necrosis, abundance of
plasma cells, and extensive collapse of liver parenchyma con-
ﬁrming the diagnosis of autoimmune hepatitis. Immediately
after biopsy, Prednisone 40mg once daily was started, which
led to rapid improvement and, eventually, normalization of
liver biochemistry. Interestingly, aFP levels also decreased
rapidly at the same rate as ALT (Figure 1). Prednisone was
slowly tapered with synchronous introduction of Azathio-
prine. At present, complete remission is maintained with
Prednisone 2,5mg and Azathioprine 150mg once daily.
3.CaseB
A 60-year-old female patient was admitted to a regional
hospital for painless jaundice, pruritus, and weight loss
after a period of epigastric pain. Physical examination
showed no abnormalities other than jaundice. Liver bio-
chemistry was consistent with obstructive jaundice (total
bilirubin 62µmol/L, conjugated bilirubin 41µmol/L, ALP
549U/L, gGT 950U/L, AST 74U/L, ALT 332U/L) but also
showed extreme elevation of Cancer Antigen (CA) 19-9
(18,000kU/L,ULN27kU/L).Abdominalultrasoundshowed
multiple stones in the gallbladder and a 13mm stone in
the distal cystic duct; there were no signs of cholecystitis.
Both the common hepatic duct and intrahepatic ducts
were dilated. During admission, liver enzymes improved
spontaneously and the patient was discharged, awaiting
cholecystectomy. However, she was readmitted with a relapse
of painless jaundice before surgery had been performed.
Abdominal CT scan now showed a dilated CBD and intra-
hepatic ducts, but no signs of malignancy. MRCP revealed
a 13mm distal CBD stone. The patient was transferred
to our hospital when she developed cholangitis. At ERCP,
stone removal from the CBD was impossible due to the
size of the gallstone, and a biliary endoprosthesis was
placed. Serum CA19-9 concentration decreased to almost
normal values (45kU/L) after biliary stenting. One month
later she was readmitted for relapse of cholangitis after
endoprothesis luxation. Again, CA19-9 was >10,000kU/L
and returned to almost normal (45kU/L) after stent place-
ment. A second attempt for endoscopic crushing and stone
extraction was not successful, and she eventually underwent
cholecystectomy with choledochotomy and stone removal.
No signs of malignancy were detected during surgery.
The histopathology of the removed gallbladder showed
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Figure 1: Serum alpha-fetoprotein (aFP) and alanine aminotrans-
ferase (ALT) concentrations in an 18-year-old male patient with
autoimmune hepatitis. Both markers normalized in several months
after treatment with Prednisone and Azathioprine was started.
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Figure 2: Serum Cancer Antigen 19-9 (CA19-9) and total bilirubin
concentrations in a 60-year-old female patient with obstructive
jaundiceduetoalargebiliarystone.Bothmarkersrapidlydecreased
after endoscopic placement of a biliary endosprothesis. Surgery was
performed in March 2009.
cholecystolithiasisandsignsofchronicinﬂammation.Serum
levels of bilirubine, and CA19-9 are shown in Figure 2.
4. Discussion
Alpha-fetoprotein is a 68-kilodalton polypeptide that is
produced in the fetal liver and yolk sac. Serum levels of aFP
are undetectable in healthy individuals but can be increased
in a number of conditions, including hepatocellular carci-
noma (HCC), seminoma and nonseminomatous germ cell
tumors, and gastric, biliary, and pancreatic cancers. Levels
of aFP can also be slightly elevated (up to 500µg/L) in
pregnancy, reﬂecting fetal production, or sometimes higherGastroenterology Research and Practice 3
in several obstetric complications. Increased levels can also
be present in chronic viral hepatitis. For instance, up to
17% of patients with chronic hepatitis C infection and
advanced ﬁbrosis or cirrhosis without evidence for HCC
have modest elevation of serum aFP concentrations, which
improve upon treatment with pegylated interferon alpha-
2a and ribavirin [1]. In general, serum concentrations
>400µg/Linhigh-riskpatients(cirrhosis,chronichepatitisB
infection) in the presence of a focal lesion of more than 2cm
with arterial hypervascularization on one imaging modality
are considered diagnostic for HCC [2]. Lower levels in
patients with HCC are common, and normal serum aFP
concentrations can be found in a signiﬁcant number of
patients with HCC [3]. False positive results may occur in
alcohol and drug abuse and other states of chronic liver
damage, but values are usually <100µg/L.
DevelopmentofHCCinpreexistingautoimmunehepati-
tis can cause serum aFP elevation as was reported previously
[4–7]. Cirrhosis was present in almost all of these patients
[4–6]o rn o tr e p o r t e d[ 7]. In our case, however, liver biopsy
did not demonstrate ﬁbrosis or cirrhosis, and abdominal
ultrasound and CT scan showed no underlying malignancy
as an explanation for the rise in aFP. Non-malignant serum
aFP elevation may result from altered hepatocyte-hepatocyte
interaction and loss of normal architectural arrangement,
such as seen in ﬁbrosis and cirrhosis [8] or, as in our case,
widespread liver tissue collapse. In contrast, experiments in
regeneratingmouselivertissueafterCCI4poisoningdemon-
strated that aFP-producing cells were normally diﬀerentiated
hepatocytes without any structural signs of damage [9].
Thus, liver tissue regeneration during hepatic inﬂammation
may be an alternative explanation for the rise in serum aFP
in our patient with autoimmune hepatitis.
To our knowledge, this paper is the ﬁrst to describe a
patient with autoimmune hepatitis and this extreme eleva-
tionofserumaFPuptolevelssuggestiveofHCC(>400µg/L)
in whom no malignancy was found. Both liver biochemistry
and aFP normalized following treatment with high-dose
glucocorticoids. A recent report described a 59-year-old
patient with a synchronous diagnosis of systemic lupus
erythematosus (SLE) and autoimmune hepatitis in whom
aFP levels were modestly elevated (320µg/L) [10]. In this
patient, levels of aFP returned to normal within weeks
aftertreatmentwithPrednisone 30mg/dayandAzathioprine
100mg/day was started. Our patient had no signs of other
underlying autoimmune diseases.
CA19-9, a tumor-associated antigen, is recognized by
the monoclonal antibody 116NS-19-9. The antigenic deter-
minant on CA19-9 that is recognized by 116NS-19-9 is a
sialylated lacto-N-fucopentaose II, the so-called sialyl Lewis
antigen. CA19-9 is used as a tumor marker of cancers in
the gastrointestinal tract, such as pancreatic and biliary tract
cancers, and colon, esophageal, and hepatic carcinomas.
CA19-9 levels may also be elevated in several benign
conditions in individuals with the Lewis antigen positive
phenotype. These include inﬂammation or proliferation of
noncancerous tissue, probably due to hypersecretion by
normal epithelial cells (i.e., pancreatitis, pancreatic cysts,
cholangitis, bronchiectasis, and pulmonary ﬁbrosis) and
obstruction of CA19-9 discharge pathways. The correla-
tion between serum CA19-9 levels and serum cholestasis
parameters (ALP, bilirubin) is well established, and CA19-
9 elevation in biliary obstruction is probably caused by
leakage of biliary mucins into the serum (i.e., pancreatic
or biliary duct stenosis due to gallstones). Malfunction in
organs that metabolize CA19-9 (chronic hepatitis, chronic
glomerulonephritis) may also lead to elevated serum levels
of CA19-9 [11]. Generally, levels greater than 1,000kU/L are
rare in benign conditions, although one study found CA19-
9l e v e l so f>1,000 U/ml to be present in 4.7% of patients
with cholangitis or cholestasis secondary to benign disease
[11–13].
On initial presentation, our patient probably had
obstructive jaundice due to Mirizzi’s syndrome. CA19-9 was
routinely measured in the workup for painless jaundice
and was extremely elevated to a maximum of 18,000kU/L.
Onlyonepreviouscasereportdemonstratedhighlyincreased
levels of CA19-9 in a patient with Mirizzi’s syndrome
[14]. The clear correlation between serum concentrations of
CA19-9, ALP and bilirubin, with normalization after biliary
stent placement in the absence of tumor on CT-scan and
ERCP,stronglysuggeststhattheelevationofCA19-9wasdue
to cholestasis and not caused by malignant disease.
In conclusion, these two cases not only demonstrate that
tumor markers can be elevated in benign disease but also
emphasize that elevated serum tumor markers alone are not
suitable for establishing a diagnosis of malignancy.
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